Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 2201 - 2300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 2201 | 26720007 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2202 | 26720025 |
US |
54 | 2 |
Rash erythematous, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, FLUOCINONIDE, FLUOCINONIDE TOPICAL SOLUTION USP, 0.05%, |
||||
| 2203 | 26720027 |
US |
38 | 2 |
Dermatitis atopic, Skin exfoliation, Pain of skin, Pruritus, Eczema, |
||||
DUPILUMAB, |
||||
| 2204 | 26720032 |
US |
52 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2205 | 26720034 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2206 | 26720036 |
US |
22 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2207 | 26720069 |
US |
5 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2208 | 26720072 |
US |
1 | |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, PRASUGREL, |
||||
| 2209 | 26720077 |
US |
60 | 1 |
Skin haemorrhage, Skin weeping, Dry skin, Skin fissures, Skin exfoliation, Pruritus, Drug ineffective, Blood pressure increased, Dermatitis atopic, Skin burning sensation, Stress, Flushing, Erythema, |
||||
DUPILUMAB, AMLODIPINE, |
||||
| 2210 | 26720087 |
US |
43 | 2 |
Dermatitis atopic, Erythema, Pain in extremity, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2211 | 26720094 |
US |
48 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2212 | 26720100 |
US |
1 | 2 |
Dermatitis atopic, Scratch, Erythema, Skin erosion, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2213 | 26720106 |
US |
56 | 1 |
Urticaria, Eye infection, Conjunctivitis, Dermatitis atopic, Erythema, Skin fissures, Skin exfoliation, Dry skin, Drug ineffective, |
||||
DUPILUMAB, DUPILUMAB, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, LORATADINE, LORATADINE TABLET, FISH OIL, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, DARIDOREXANT, ERGOCALCIFEROL, REMIBRUTINIB, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, |
||||
| 2214 | 26720148 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2215 | 26720190 |
US |
47 | 1 |
Dermatitis atopic, Disease recurrence, Pruritus, Chapped lips, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 2216 | 26720219 |
US |
1 | |
Dermatitis atopic, Rash, Pruritus, |
||||
DUPILUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 2217 | 26720285 |
US |
8 | 2 |
Discomfort, Urticaria, Pustule, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2218 | 26720515 |
CA |
2 | |
Dermatitis atopic, Product use issue, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 2219 | 26720587 |
CA |
5 | 2 |
Dermatitis atopic, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, METHYLPREDNISOLONE, |
||||
| 2220 | 26720675 |
US |
65 | |
Dermatitis atopic, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 2221 | 26713383 |
US |
17 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2222 | 26713387 |
US |
55 | 2 |
Rash erythematous, Pruritus, Skin burning sensation, Dermatitis atopic, Idiopathic urticaria, Arthropod bite, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2223 | 26713397 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2224 | 26713501 |
US |
43 | 2 |
Sleep disorder, Skin haemorrhage, Skin fissures, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2225 | 26713683 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2226 | 26713708 |
US |
48 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2227 | 26713715 |
US |
22 | 2 |
Injection site vesicles, Injection site mass, Injection site rash, Dermatitis atopic, Rash, Drug ineffective, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2228 | 26713716 |
US |
85 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2229 | 26713721 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2230 | 26713819 |
US |
15 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2231 | 26713845 |
US |
2 | |
Dermatitis atopic, Skin swelling, Pruritus, |
||||
DUPILUMAB, |
||||
| 2232 | 26713853 |
US |
75 | 2 |
Eczema, Pruritus, Pain, Exposure via skin contact, Accidental exposure to product, Incorrect dose administered, Dermatitis atopic, Neuralgia, Diarrhoea, Sensitive skin, |
||||
DUPILUMAB, DUPILUMAB, ETANERCEPT, ABATACEPT, |
||||
| 2233 | 26713896 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2234 | 26713899 |
US |
15 | 2 |
Fungal infection, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2235 | 26713900 |
US |
8 | 1 |
Fear of injection, Dermatitis atopic, Pruritus, Dry skin, Skin exfoliation, Therapeutic response shortened, Erythema, |
||||
DUPILUMAB, |
||||
| 2236 | 26713902 |
US |
5 | 1 |
Epistaxis, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2237 | 26713911 |
US |
63 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2238 | 26713913 |
US |
66 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2239 | 26713949 |
US |
35 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2240 | 26713954 |
US |
48 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2241 | 26713985 |
US |
78 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2242 | 26713996 |
US |
28 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2243 | 26713997 |
US |
10 | 1 |
Dermatitis atopic, Dermatitis, Drug ineffective, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2244 | 26714005 |
US |
35 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2245 | 26714006 |
US |
61 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2246 | 26714015 |
US |
1 | |
Dermatitis atopic, Intentional dose omission, |
||||
DUPILUMAB, |
||||
| 2247 | 26714016 |
US |
64 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2248 | 26714136 |
US |
75 | 1 |
Pruritus, Dermatitis atopic, Rash, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, NEMOLIZUMAB-ILTO, |
||||
| 2249 | 26714138 |
US |
5 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2250 | 26714212 |
US |
30 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2251 | 26714216 |
US |
15 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2252 | 26714247 |
US |
13 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2253 | 26714259 |
US |
16 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2254 | 26714275 |
US |
39 | 2 |
Dermatitis atopic, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 2255 | 26714276 |
US |
39 | 1 |
Dermatitis atopic, Product dose omission issue, Rash erythematous, Pruritus, Skin burning sensation, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2256 | 26714302 |
US |
47 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2257 | 26714325 |
US |
29 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, LEVONORGESTREL, |
||||
| 2258 | 26714336 |
US |
38 | 2 |
Dermatitis atopic, Eczema, Blister, |
||||
DUPILUMAB, |
||||
| 2259 | 26714343 |
US |
62 | 2 |
Arthritis, Dermatitis atopic, |
||||
DUPILUMAB, ABATACEPT, |
||||
| 2260 | 26714349 |
US |
56 | 2 |
Injection site pain, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2261 | 26714357 |
US |
1 | |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, |
||||
| 2262 | 26714359 |
US |
42 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2263 | 26714369 |
US |
63 | 1 |
Injection site pain, Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2264 | 26714403 |
US |
2 | |
Dermatitis atopic, Dry skin, Pruritus, |
||||
DUPILUMAB, |
||||
| 2265 | 26714406 |
US |
47 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2266 | 26714417 |
US |
23 | 1 |
Dermatitis atopic, Incorrect dose administered, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2267 | 26714418 |
US |
17 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2268 | 26714419 |
US |
71 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2269 | 26714421 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2270 | 26714422 |
US |
11 | 1 |
Dermatitis atopic, Dry skin, Rash erythematous, Pruritus, Skin burning sensation, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2271 | 26714431 |
US |
12 | 2 |
Rash, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2272 | 26714446 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2273 | 26714473 |
US |
31 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2274 | 26714480 |
US |
41 | 2 |
Dermatitis atopic, Pruritus, Dry skin, Product dose omission issue, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, TRALOKINUMAB-LDRM, |
||||
| 2275 | 26714500 |
US |
48 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2276 | 26714506 |
US |
82 | 1 |
Discomfort, Sleep disorder due to a general medical condition, Dry skin, Skin exfoliation, Pruritus, Therapeutic response decreased, Inappropriate schedule of product administration, Dermatitis atopic, Rash, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 2277 | 26714512 |
US |
33 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2278 | 26714529 |
US |
1 | |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2279 | 26714562 |
US |
58 | 2 |
Dermatitis atopic, Skin haemorrhage, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2280 | 26714566 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2281 | 26714630 |
US |
35 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2282 | 26714631 |
US |
32 | 2 |
Hormone level abnormal, Eye pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2283 | 26714657 |
US |
14 | 2 |
Dermatitis atopic, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2284 | 26714684 |
US |
5 | 2 |
Eye allergy, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2285 | 26714692 |
US |
68 | 1 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, |
||||
| 2286 | 26714805 |
US |
60 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2287 | 26714813 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2288 | 26715015 |
US |
36 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2289 | 26715412 |
US |
1 | |
Dry eye, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2290 | 26716667 |
US |
43 | 2 |
Dermatitis atopic, Cheilitis, |
||||
DUPILUMAB, |
||||
| 2291 | 26705635 |
CO |
27 | 2 |
Sepsis, Immunosuppression, Pyrexia, Hypotension, Haemoglobin decreased, Renal abscess, Hospitalisation, Urinary tract infection, Escherichia infection, Pain, Eczema, Dermatitis atopic, Gastritis, Back pain, Pyrexia, Erythema, Rash maculo-papular, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2292 | 26706922 |
KR |
49 | 1 |
Aplastic anaemia, Dermatitis atopic, |
||||
CYCLOSPORINE, CYCLOSPORINE, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 2293 | 26707574 |
US |
81 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2294 | 26707615 |
US |
7 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2295 | 26707620 |
US |
14 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2296 | 26707624 |
US |
93 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2297 | 26707665 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2298 | 26707673 |
US |
20 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2299 | 26707801 |
US |
34 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2300 | 26707849 |
US |
14 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30